These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33096424)

  • 1. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
    Biterge Süt B
    Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection.
    Saitta C; Lanza M; Bertuccio A; Lazzara S; Navarra G; Raimondo G; Pollicino T
    Cancer Genet; 2015 Oct; 208(10):513-6. PubMed ID: 26341700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
    Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
    Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinomas with Concomitant Mutations of TERT, TP53, and CTNNB1: Is There a Role for Artificial Intelligence?
    Chillotti S; Maloberti T; Degiovanni A; Malvi D; D'Errico A; de Biase D; Vasuri F
    Crit Rev Oncog; 2023; 28(3):31-35. PubMed ID: 37968991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
    Huang X; Yang C; Wang J; Sun T; Xiong H
    Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
    Xiao X; Mo H; Tu K
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
    Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
    Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
    Hosny G; Farahat N; Tayel H; Hainaut P
    Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and histological correlations in liver cancer.
    Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
    J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
    J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.